Collectively, these findings introduce a novel, noninvasive biomarker for early detection, risk stratification, and monitoring of anti‐LGI1 encephalitis, while offering fresh insights into the metabolic mechanisms underlying pathogenesis of clinical manifestations. The gene discussed is LGI1; the disease is viral encephalitis.